Assessing Barriers to Oral Oncolytic Adherence
Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
